Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OA-002v
- Development stage
- Unknown
- Lead developer
- Allegro
- Modality
- Small Molecules
01
Overview
OA-002v is an investigational therapeutic candidate developed by Allegro for the treatment of osteoarthritis. It belongs to the company's proprietary "Intricate" class of medicines, which are focused on addressing rheumatology, orthopedics, and musculoskeletal diseases. As of early 2024, OA-002v is in Phase 1/2 clinical development, appearing as one of the more advanced assets in Allegro's pipeline for joint-related conditions. While the specific molecular target and mechanism of action have not been publicly disclosed, the drug is part of a platform designed to provide targeted interventions for degenerative bone and joint disorders.
Beyond the preview
Go deeper on OA-002v.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OA-002v.